Our current paper is centered around a very unique and intriguing clinical case of a high-risk bladder tumor, occurring and progressing after the initiation of anti-BRAF/MEK chemotherapy for a concurrent, advanced, BRAF V600E positive, malignant melanoma (MM), which then demonstrated complete spontaneous bladder tumor necrosis, as a consequence of the newly instated Nivolumab immunotherapy, aimed at addressing the MM progression under chemotherapy. Here, MAP2K7 is linked to urinary bladder neoplasm.